Episode notes
In this episode of Well Yes, HUM Nutrition co-founder Walter Faulstroh and registered dietitian Sarah Greenfield, RD, dive deep into the GLP-1 weight loss microdosing trend—including semaglutide (Ozempic) and tirzepatide (Mounjaro)—and explore how far people are going to experiment with these drugs in pursuit of better health, body composition, and longevity.
They unpack the science behind GLP-1s, the rise of microdosing culture, and why some wellness enthusiasts are blurring the lines between medicine and lifestyle. Tune in for a real, science-backed discussion about self-experimentation, biohacking, and the future of wellness—plus, when the trend goes too far.
🔍
Keywords
HEALTHWELLNESSDIETWEIGHTGLP1GLP-1